Clinical features, pathogenesis, and treatment of Guillain-Barré syndrome

@article{Doorn2008ClinicalFP,
  title={Clinical features, pathogenesis, and treatment of Guillain-Barr{\'e} syndrome},
  author={Pieter A. Doorn and Liselotte Ruts and Bart C. Jacobs},
  journal={The Lancet Neurology},
  year={2008},
  volume={7},
  pages={939-950}
}

Figures from this paper

Guillain–Barré syndrome: pathogenesis, diagnosis, treatment and prognosis
TLDR
Novel prognostic models can accurately predict outcome and the need for artificial ventilation, which could aid the selection of patients with a poor prognosis for more-individualized care.
IVIG Treatment and Prognosis in Guillain–Barré Syndrome
TLDR
A recent retrospective study in 174 GBS patients enrolled in one of the randomized controlled clinical trials showed that patients with a minor increase of serum IgG level after standard single IVIg dose recovered significantly slower, and fewer patients reached the ability to walk unaided at six months after correction for the known clinical prognostic factors.
The investigation of guillain-barre syndrome and prognosis
TLDR
In this study, age, respiratory failure, cranial nerve involvement and N/L ratio were found as related factors with short-term prognosis with Guillain-Barre Syndrome.
The immunotherapy of Guillain-Barré syndrome
TLDR
This review offers a comprehensive view of the current treatment based upon the physiopathology of Guillain-Barré syndrome, finding new biomarkers and establishing algorithms of prediction of both the disease and its outcomes is warranted.
Recent Concepts of Guillain-Barré Syndrome
TLDR
The discovery of anti-ganglioside antibodies on the basis of molecular mimicry theory could help to better understand various kinds of focal and regional variants as well as axonal type of GBS those were frequently found from Asian countries.
Immunopathogenesis and Treatment of Guillain-Barre Syndrome and Chronic Inflammatory Demyelinating Polyneuropathy
This chapter discusses the clinical manifestations, pathogenesis, and treatment of Guillain-Barre syndrome (GBS) and chronic inflammatory demyelinating polyneuropathy (CIDP), including recent
Emerging drugs for Guillain-Barré syndrome
TLDR
Intravenous immunoglobulin (IVIg) and plasma exchange are proven effective treatments for Guillain-Barré syndrome, a heterogeneous disease with considerable short- and long-term disability for which more effective and individualized treatments are required.
Severe Guillain-Barré syndrome
The Guillain-Barré syndrome.
  • H. Fujimura
  • Biology, Medicine
    Handbook of clinical neurology
  • 2013
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 185 REFERENCES
Infections and course of disease in mild forms of Guillain–Barré syndrome
TLDR
The difference in severity of Guillain–Barré syndrome seems to be determined in an early phase of the disease, and the presence of residual signs in patients with mild disease may advocate the use of early treatment in mildly affected patients.
Clinical features and response to treatment in Guillain‐Barré syndrome associated with antibodies to GM1b ganglioside
TLDR
The distinctive clinical features of the patients with anti‐GM1b antibodies show that acute motor neuropathy represents a specific subgroup within GBS and that recognizing these patients may have consequences as to the choice of therapy.
Treatment of Guillain–Barré syndrome with mycophenolate mofetil: a pilot study
TLDR
An open label pilot study to assess the additional effect of MM, administered simultaneously with IVIg and MP, in patients with GBS and whether there is a tendency to improved outcome.
Preceding infections, immune factors, and outcome in Guillain–Barré syndrome
TLDR
Subtypes of GBS defined by preceding infections were only approximately associated with different patterns of clinical, neurophysiologic, and immunologic features, implying interaction with additional host factors.
The immunopathogenesis of Miller Fisher syndrome
[Guillain-Barré syndrome].
TLDR
High-dose of intravenous immunoglobulin (0.4 g/kg daily for 5 days) and PE are equally effective in intermediate and severe forms and the choice between the two treatments depends on their respective contra-indications and local availability.
Risk factors for treatment related clinical fluctuations in Guillain-Barré syndrome
TLDR
It is suggested that treatment related clinical fluctuations are due to a more prolonged immune attack after a protracted disease course.
Guillain-Barré syndrome
Guillain-Barré syndrome and chronic inflammatory demyelinating polyneuropathy: Immune mechanisms and update on current therapies
TLDR
In Guillain-Barre syndrome the efficacy of high-dose intravenous immune globulin treatment was established after earlier positive findings with plasma exchange; immune globulins are easier to administer and may be superior, and complexity and costs make plasma exchange the last choice.
The spectrum of antecedent infections in Guillain-Barré syndrome
TLDR
To determine which antecedent infections are specifically associated with the Guillain-Barré syndrome, a serologic study in 154 GBS patients and 154 sex- and age-matched controls with other neurologic diseases found that C. jejuni, cytomegalovirus, Epstein-Barr virus, and M. pneumoniae are specifically related to GBS.
...
1
2
3
4
5
...